Biomarker ID | 474 |
PMID | 19652763 |
Year | 2009 |
Biomarker | CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include (CCNB1): T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway |
Experiment | Tumor Vs Adjacent To Tumor |
Type of Biomarker | Diagnostic |
Cohort | 148 patients such as 23 were organ donors, 59 adjacent to Tumor, and 66 Tumor samples were included. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | Validation Set: 93.9% |
Level Of Significance | p=0.05 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Using Prostate cancer as the training set, Liver samples were predicted with 97.7% accuracy, Lung cancer as 94.5% accuracy and Bladder cancer with 88.3% accuracy |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | CCNB1: BUB1B: CLDN4: PCLAF: SLC39A6: SOX4: TOP2A: |